ACP
DRUG

Acuta Capital Partners’s Bright Minds Biosciences DRUG Stock Holding History

Acuta Capital Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.51M Sell
92,745
-19,251
-17% -$1.51M 4.54% 7
2026
Q1 		$8.17M Buy
111,996
+27,519
+33% +$2.22M 5.77% 5
2025
Q4 		$6.59M Sell
84,477
-398
-0.5% -$26.6K 4.48% 6
2025
Q3 		$5.15M Buy
84,875
+36,401
+75% +$1.41M 5.32% 6
2025
Q2 		$1.27M Sell
48,474
-11,274
-19% -$338K 1.77% 17
2025
Q1 		$2.16M Sell
59,748
-9,376
-14% -$343K 2.5% 15
2024
Q4 		$2.49M Buy
+69,124
New +$2.43M 2.5% 14

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Acuta Capital Partners's DRUG Position: Q2 2026 in Review

Acuta Capital Partners reduced its Bright Minds Biosciences (DRUG) stake by 17% in Q2 2026, selling an estimated $1.51M and leaving 92,745 shares worth $6.51M. The position accounts for 4.54% of the portfolio, ranked #7.

Acuta Capital Partners first reported a position in DRUG in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.17M in Q1 2026. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Acuta Capital Partners held 92,745 shares of Bright Minds Biosciences worth $6.51M as of Q2 2026.
  • Acuta Capital Partners sold 19,251 Bright Minds Biosciences shares in Q2 2026, an estimated $1.51M.
  • Bright Minds Biosciences made up 4.54% of Acuta Capital Partners's portfolio in Q2 2026, its #7 holding.
  • Acuta Capital Partners first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Acuta Capital Partners's Bright Minds Biosciences position peaked at $8.17M in Q1 2026.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.